GAL-021 | CAS#1380341-99-0 | BKCa-Channel Blocker

MedKoo Cat#: 528001 | Name: GAL-021

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GAL-021 is a large conductance calcium-activated potassium channel (BKCa-channel) blocker potentially for the treatment of respiratory depression. GAL-021 inhibited KCa1.1 in GH3 cells, and the evoked ventilatory stimulation was attenuated in Slo1 mice lacking the pore-forming α-subunit of the KCa1.1 channel. At a higher concentration of GAL-160 (100 μM), inhibition of the delayed rectifier K(+) current and leak K(+) current were observed.

Chemical Structure

GAL-021

CAS#1380341-99-0

Theoretical Analysis

MedKoo Cat#: 528001

Name: GAL-021

CAS#: 1380341-99-0

Chemical Formula: C11H22N6O

Exact Mass: 254.1855

Molecular Weight: 254.34

Elemental Analysis: C, 51.95; H, 8.72; N, 33.04; O, 6.29

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 850.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,150.00	2 Weeks
1g	USD 3,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GAL-021; GAL 021; GAL021

IUPAC/Chemical Name

6-(methoxy(methyl)amino)-N2,N4-dipropyl-1,3,5-triazine-2,4-diamine

InChi Key

FJNLCHNQVJVCPY-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H22N6O/c1-5-7-12-9-14-10(13-8-6-2)16-11(15-9)17(3)18-4/h5-8H2,1-4H3,(H2,12,13,14,15,16)

SMILES Code

CCCNC1=NC(N(OC)C)=NC(NCCC)=N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 254.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Golder FJ, Dax S, Baby SM, Gruber R, Hoshi T, Ideo C, Kennedy A, Peng S, Puskovic V, Ritchie D, Woodward R, Wardle RL, Van Scott MR, Mannion JC, MacIntyre DE. Identification and Characterization of GAL-021 as a Novel Breathing Control Modulator. Anesthesiology. 2015 Nov;123(5):1093-104. doi: 10.1097/ALN.0000000000000844. PubMed PMID: 26352381. 2: Dallas ML, Peers C, Golder FJ, Baby S, Gruber R, MacIntyre DE. GAL-021 and GAL-160 are Efficacious in Rat Models of Obstructive and Central Sleep Apnea and Inhibit BKCa in Isolated Rat Carotid Body Glomus Cells. Adv Exp Med Biol. 2015;860:361-70. doi: 10.1007/978-3-319-18440-1_41. PubMed PMID: 26303501. 3: McLeod JF, Leempoels JM, Peng SX, Dax SL, Myers LJ, Golder FJ. GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. Br J Anaesth. 2014 Nov;113(5):875-83. doi: 10.1093/bja/aeu182. PubMed PMID: 24989775. 4: Roozekrans M, Olofsen E, van der Schrier R, van Gerven J, Peng S, McLeod J, Dahan A. Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Clin Pharmacol Ther. 2015 Jun;97(6):641-9. doi: 10.1002/cpt.99. PubMed PMID: 25704491. 5: Roozekrans M, van der Schrier R, Okkerse P, Hay J, McLeod JF, Dahan A. Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers. Anesthesiology. 2014 Sep;121(3):459-68. doi: 10.1097/ALN.0000000000000367. PubMed PMID: 25222672. 6: van der Schier R, Roozekrans M, van Velzen M, Dahan A, Niesters M. Opioid-induced respiratory depression: reversal by non-opioid drugs. F1000Prime Rep. 2014 Sep 4;6:79. doi: 10.12703/P6-79. Review. PubMed PMID: 25343036; PubMed Central PMCID: PMC4173639. 7: Golder FJ, Hewitt MM, McLeod JF. Respiratory stimulant drugs in the post-operative setting. Respir Physiol Neurobiol. 2013 Nov 1;189(2):395-402. doi: 10.1016/j.resp.2013.06.010. Review. PubMed PMID: 23791825. 8: Cotten JF. The latest pharmacologic ventilator. Anesthesiology. 2014 Sep;121(3):442-4. doi: 10.1097/ALN.0000000000000368. PubMed PMID: 25222671; PubMed Central PMCID: PMC4166568. 9: Xie Y, Puscheck EE, Rappolee DA. Effects of SAPK/JNK inhibitors on preimplantation mouse embryo development are influenced greatly by the amount of stress induced by the media. Mol Hum Reprod. 2006 Apr;12(4):217-24. PubMed PMID: 16574700.